pharma · Lymphoma of B-cell origin · Malignant Solid Tumors
Genmab
Genmab A/S
Genmab A/S is a pharma organization headquartered in Valby, DK. Primary therapeutic focus areas include Lymphoma of B-cell origin, Malignant Solid Tumors, Metastatic or advanced malignant solid tumors, Non-Small Cell Lun
Carl Jacobsens Vej 30, 2500 Valby, DK HQ
2,847 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Carl Jacobsens Vej 30, 2500 Valby, DK
- Employees
- 2,847
- Programs
- 29
- Drugs
- 56
- Patents
- 0
GCT3018-01
Phase 1 · other · Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
GCT3018-01 for Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome is a Phase 1 program (other) at Genmab A/S with 1 ClinicalTrials.gov record(s).
Internal code GCT3018-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Genmab A/S
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
- Status
- active
- Trials
- 1